AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
A 6-day course of acetazolamide appeared to improve sleep-disordered breathing in a study of 12 men with heart failure-related central sleep apnea.
In central sleep apnea (CSA), respiration temporarily ceases because of a decline in partial pressure of carbon dioxide (PC[O.sub.2]) below the apneic threshold. However, in a randomized, double-blind study by Dr. Shahrokh Javaheri and his associates, the diuretic and respiratory stimulant acetazolamide seemed to reduce the likelihood of PC[O.sub.2] crossing the apneic threshold by inducing a state of metabolic acidosis. Dr. Javaheri of the University of Cincinnati and associates evaluated acetazolamide in 12 men with stable heart failure with left ventricular systolic dysfunction and CSA (Am. J. Respir. Crit. Care Med. 2006;173:234-7).
For 6 nights, patients received either placebo or a single dose (3.5 mg/kg) of acetazolamide and 30 mEq of potassium chloride (to offset the urinary potassium loss ...